Amarantus BioScience Opens Investigational New Drug (IND) Application With the U.S. Food and Drug Administration Allowing the Start of a Phase 2b Program of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia
Amarantus to Present Positive Alzheimer's Disease Biomarker Data on the LymPro Test(R) at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
Amarantus Announces First Alzheimer's Biomarker Services Collaboration for LymPro Test(R) With Anavex Life Sciences Corp.
Amarantus Announces Publication in BRAIN of Eltoprazine Phase 2a Clinical Study for Treating Parkinson's Disease Levodopa-Induced Dyskinesia
Amarantus BioScience Holdings, Inc.
655 Montgomery Street
San Francisco, CA 94111
Phone: (415) 688-4484
Fax: (408) 852-4427
Jenene Thomas Communications, LLC
Jenene Thomas, Investor Relations and Corporate Communications Advisor
Phone: (908) 938-1475
Forward Looking Statements
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.